Persistent quality of life impairments in differentiated thyroid cancer patients: results from a monitoring programme

被引:71
|
作者
Gamper, Eva-Maria [1 ,2 ]
Wintner, Lisa M. [2 ]
Rodrigues, Margarida [1 ]
Buxbaum, Sabine [1 ]
Nilica, Bernhard [1 ]
Singer, Susanne [3 ]
Giesinger, Johannes M. [4 ]
Holzner, Bernhard [2 ]
Virgolini, Irene [1 ]
机构
[1] Med Univ Innsbruck, Dept Nucl Med, A-6020 Innsbruck, Austria
[2] Med Univ Innsbruck, Dept Psychiat & Psychotherapy, A-6020 Innsbruck, Austria
[3] Johannes Gutenberg Univ Mainz, Inst Med Biostat Epidemiol & Informat, D-55122 Mainz, Germany
[4] Netherlands Canc Inst, Amsterdam, Netherlands
基金
奥地利科学基金会;
关键词
Differentiated thyroid cancer; Health-related quality of life; Radioiodine remnant ablation; HORMONE WITHDRAWAL; CARCINOMA PATIENTS; PROFILES REGISTRY; SURVIVORS; RADIOIODINE; FATIGUE; DISEASE; POPULATION; ABLATION; THERAPY;
D O I
10.1007/s00259-015-3022-9
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose Health-related quality of life (HRQOL) in differentiated thyroid cancer (DTC) research has so far received little attention and available results are conflicting. We studied the HRQOL of radioiodine-naive DTC patients in comparison with the general population (GP), investigated the course of HRQOL up to 30 months after radioiodine remnant ablation (RAA) and sought to identify patient characteristics associated with HRQOL. Methods We analysed data from routine HRQOL monitoring at a nuclear medicine department. Between 2005 and 2013, a total of 439 thyroid cancer patients (all histologies) completed the EORTC Quality of Life Questionnaire Core-30 (QLQ-C30) at least once during their treatment at the department. We compared patients' baseline HRQOL scores before RAA with scores from age-matched and sex-matched controls from the Austrian GP. We then determined the course of HRQOL over the 30 months after RAA and assessed the impact of the following clinical variables on HRQOL: method of thyroid-stimulating hormone (TSH) stimulation, histology (papillary vs. follicular) and disease stage. Results A total of 284 patients (mean age 48.3 years, SD 15.0 years; 71.6 % women; 80.7 % papillary type) with a baseline HRQOL assessment before RAA were available. We found clinically meaningful differences in the detriment in patients on almost all domains. These were largest for fatigue (23 points) and role functioning (25 points). Data from 241 patients (mean age 48.6 years, SD 15.9 years; 68.9 % women; 76.3 % papillary type) were included in the longitudinal analysis. Investigating the course of HRQOL, a significant improvement over time was found for role and emotional functioning, fatigue, pain, and dyspnoea. A range of HRQOL scores were improved in patients with exogenous TSH stimulation, but some scores both in patients with exogenous TSH stimulation and in those followed for 30 months, especially fatigue and role functioning, did not reach levels in the GP sample. Conclusion Our results show that the favourable prognosis of DTC does not directly translate into good HRQOL in these patients. Persistent restrictions in regaining their normal daily life in terms of work and leisure highlight the importance of more detailed investigation of DTC patients' wellbeing, support needs, and disease experience.
引用
收藏
页码:1179 / 1188
页数:10
相关论文
共 50 条
  • [31] Quality of life of patients with thyroid cancer in Colombia
    Gomez, Oscar
    Sanabria, Alvaro
    ENDOCRINOLOGIA DIABETES Y NUTRICION, 2024, 71 (02): : 61 - 70
  • [32] Quality of life and distress of patients with thyroid cancer
    Gamper, E. -M.
    Sztankay, M.
    ONKOLOGE, 2015, 21 (07): : 625 - 629
  • [33] Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: Results from the National Thyroid Cancer Treatment Cooperative Registry
    Cooper, DS
    Specker, B
    Ho, M
    Sperling, M
    Ladenson, PW
    Ross, DS
    Ain, KB
    Bigos, ST
    Brierley, JD
    Haugen, BR
    Klein, I
    Robbins, J
    Sherman, SI
    Taylor, T
    Maxon, HR
    THYROID, 1998, 8 (09) : 737 - 744
  • [34] Effect of radioiodine therapy under thyroid hormone withdrawal on health-related quality of life in patients with differentiated thyroid cancer
    Ming, Hui
    Yu, Hui
    Liu, Yangbao
    Yang, Lihua
    Chen, Yuanhao
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2022, 52 (10) : 1159 - 1166
  • [35] Health-Related Quality of Life in Asian Differentiated Thyroid Cancer Survivors
    Chan, Wing-Lok
    Choi, Horace Cheuk-Wai
    Lang, Brian
    Wong, Kai-Pun
    Yuen, Kwok-Keung
    Lam, Ka-On
    Lee, Victor Ho-Fun
    Kwong, Dora
    CANCER CONTROL, 2021, 28
  • [36] Quality of life with well-differentiated thyroid cancer: Treatment toxicities and their reduction
    Mendoza, A
    Shaffer, B
    Karakla, D
    Mason, ME
    Elkins, D
    Goffman, TE
    THYROID, 2004, 14 (02) : 133 - 140
  • [37] Serum thyroglobulin in the monitoring of differentiated thyroid cancer
    Evans, Carol
    Tennant, Sarah
    Perros, Petros
    SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 2016, 76 : S119 - S123
  • [38] Real-life use of lenvatinib in patients with differentiated thyroid cancer: experience from Argentina
    Fernando Jerkovich
    Inés Califano
    Fernanda Bueno
    Juan Manuel Carrera
    Raúl Giglio
    Erika Abelleira
    Fabián Pitoia
    Endocrine, 2020, 69 : 142 - 148
  • [39] Real-life use of lenvatinib in patients with differentiated thyroid cancer: experience from Argentina
    Jerkovich, Fernando
    Califano, Ines
    Bueno, Fernanda
    Manuel Carrera, Juan
    Giglio, Raul
    Abelleira, Erika
    Pitoia, Fabian
    ENDOCRINE, 2020, 69 (01) : 142 - 148
  • [40] Radioactive Iodine Administration Is Associated with Persistent Related Symptoms in Patients with Differentiated Thyroid Cancer
    Florenzano, Pablo
    Guarda, Francisco J.
    Jaimovich, Rodrigo
    Droppelmann, Nicolas
    Gonzalez, Hernan
    Dominguez, Jose M.
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY, 2016, 2016